Ensign Peak Advisors, Inc Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Ensign Peak Advisors, Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$83.14 - $145.99 $2.83 Million - $4.97 Million	-34,014 Reduced 24.87%	102,726 $15 Million
Q1 2022 May 16, 2022	BUY	$110.08 - $142.92 $1.58 Million - $2.05 Million	14,327 Added 11.7%	136,740 $16.2 Million
Q4 2021 Feb 11, 2022	BUY	$99.73 - $148.48 $2.88 Million - $4.29 Million	28,921 Added 30.93%	122,413 $16.9 Million
Q3 2021 Nov 12, 2021	BUY	$98.85 - $138.91 $1.39 Million - $1.95 Million	14,031 Added 17.66%	93,492 $13 Million
Q2 2021 Aug 13, 2021	BUY	$65.78 - $105.02 $898,094 - $1.43 Million	13,653 Added 20.75%	79,461 $7.71 Million
Q1 2021 May 12, 2021	BUY	$64.07 - $91.75 $1.89 Million - $2.71 Million	29,522 Added 81.36%	65,808 $4.5 Million
Q3 2020 Nov 12, 2020	SELL	$59.04 - $77.95 $1.67 Million - $2.2 Million	-28,256 Reduced 43.78%	36,286 $2.36 Million
Q2 2020 Aug 12, 2020	BUY	$29.01 - $74.23 $535,785 - $1.37 Million	18,469 Added 40.09%	64,542 $4.72 Million
Q1 2020 May 11, 2020	BUY	$27.51 - $57.29 $567,998 - $1.18 Million	20,647 Added 81.2%	46,073 $1.57 Million
Q4 2019 Feb 14, 2020	BUY	$40.86 - $57.65 $1.04 Million - $1.47 Million	25,426 New	25,426 $1.38 Million

785K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.65B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ensign Peak Advisors, Inc with notifications on news.